Brief: Kinnate Biopharma Inc. Announces FDA Clearance Of Investigational Drug Application For Kin-3248
18/01/2022 21:23
Jan 18 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL DRUG APPLICATION FOR KIN-3248
* KINNATE BIOPHARMA INC- PHASE 1 TRIAL OF KIN-3248 IS
EXPECTED TO
INITIATE IN FIRST HALF OF 2022
Source text for Eikon: ID:nGNX1cQSTN
Further company coverage: KNTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview